Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01847014 · ClinicalTrials.gov registry record · Phase 3

Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument

A Phase 3 study, sponsored by Actelion.

Terminated
Registry status
Phase 3
Development phase
4
Enrollment target

NCT01847014 is a Phase 3 study that was terminated before completion, run by Actelion. The registered enrollment target is 4 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01847014, a Phase 3 study, was terminated before completion, sponsored by Actelion.

TERMINATED
Registry status
Phase 3
Development phase
4 participants
Enrollment target

Study Summary

SYMPHONY Extension is an extension of AC-055-401, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument. The objective is to assess the long-term safety of macitentan in subjects with PAH beyond the treatment in the AC-055-401 study.

Interventions

  • DRUG Macitentan

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2013-09-01
Est. Completion 2017-11-30
Phase Phase 3

Sponsor

Actelion

63 total trials

What the Registry Record Tells You About NCT01847014

The ClinicalTrials.gov registry entry for NCT01847014 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Macitentan is the first listed.

NCT01847014 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01847014 about?

NCT01847014 is a clinical study titled "Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument". SYMPHONY Extension is an extension of AC-055-401, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument. The objective is to assess the long-term safety of macitentan in subjects w...

What is the current status of trial NCT01847014?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2013-09-01. Estimated completion is 2017-11-30.

What interventions are being tested in trial NCT01847014?

The interventions under investigation include: Macitentan (DRUG).

Who is sponsoring clinical trial NCT01847014?

This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.